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A B S T R A C T
The value of human pluripotent stem cells (hPSC) in regenerative medicine has yet to reach its full potential. The road from basic research tool to clinically validated
PSC-derived cell therapy products is a long and winding one, leading researchers, clinicians, industry and regulators alike into undiscovered territory. All stake-
holders must work together to ensure the development of safe and effective cell therapies. Similarly, utilization of hPSC in meaningful and controlled disease
modeling and drug screening applications requires information on the quality and suitability of the applied cell lines. Central to these common goals is the complete
documentation of hPSC data, including the ethical provenance of the source material, the hPSC line derivation, culture conditions and genetic constitution of the
lines. Data surrounding hPSC is scattered amongst diverse sources, including publications, supplemental data, researcher lab books, accredited lab reports, certi-
ficates of analyses and public data repositories. Not all of these data sources are publicly accessible nor associated with metadata nor stored in a standard manner,
such that data can be easily found and retrieved. The Human Pluripotent Stem Cell Registry (hPSCreg; https://hpscreg.eu/) was started in 2007 to impart provenance
and transparency towards hPSC research by registering and collecting standard properties of hPSC lines. In this chapter, we present a short primer on the history of
stem cell-based products, summarize the ethical and regulatory issues introduced in the course of working with hPSC-derived products and their associated data, and
finally present the Human Pluripotent Stem Cell Registry as a valuable resource for all stakeholders in therapies and disease modeling based on hPSC-derived cells.
1. Introduction
1.1. Stem cells in regenerative medicine
Stem cell therapy has garnered unprecedented fame and infamy in
the last two decades, skyrocketing in part to the breakthrough discovery
of induced pluripotent stem cells (iPSC) in 2006 (Takahashi and
Yamanaka, 2006). Prior to iPSC, the field of stem cell research was
driven by embryonic stem cells (ESC) and somatic stem cells (SSC),
each with its own advantages and disadvantages. While human ESC
have the versatility to form hundreds of cell types from all three germ
layers, their routine use as an unlimited source of pluripotent cells is
confronted with ethical considerations and restrictive regulations re-
garding the use of donated human embryos leftover from IVF treatment
(Reisman and Adams, 2014). The sources of somatic stem cells, on the
other hand, do not rely on ethically sensitive embryonic material and
are easier to access. Importantly for cell-based therapies, patient-de-
rived SSC represent a renewable source of autologous cells, which
should in principle reduce the risk of transplant rejection. However,
SSC are multipotent or unipotent and are only able to differentiate into
cell types of the same lineage, and may have limited proliferation
ability, thus hampering large-scale production (Reisman and Adams,
2014). Currently, SSC have therapeutic applications using hemato-
poeitic (blood disorders), mesenchymal (blood disorders, graft-vs-host
disease, cartilage repair), epithelial (burn wounds), and limbal stem
cells (ocular burns) (Ahrlund-Richter et al., 2009). SSC for clinical use
form the basis for more than 500 clinical studies in the US alone
(ClinicalTrials.gov, 2018). However, there only 11 SSC-based therapies
with marketing authorization in the EU or United States and 20
worldwide (Abou-El-Enein et al., 2016; Cuende et al., 2018).
No longer limited to stem cells of restricted lineage, such as bone
marrow stromal cells or adipose-derived stromal cells, researchers can
now add to their toolbox the progenitor of almost all cells, the induced
pluripotent stem cell. Human iPSCs (hiPSC) can be generated from a
variety of cell types spanning a spectrum of plasticities, from germ and
neural stem cells to differentiated somatic cells such as fibroblasts and
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peripheral blood mononuclear cells. In contrast to hESC, the generation
of hiPSC does not require working with embryonic material and
therefore the complicated legal and ethical issues associated with em-
bryo destruction do not apply (Carvalho and Ramalho-Santos, 2013
Jun; Zheng, 2016). Generating iPSC requires more hands-on cell ma-
nipulation than ESC or SSC, which are typically isolated from existing
tissue structures and are usually not reprogrammed before use in cell
therapy. There are a variety of protocols available to generate hiPSC,
using genome-integrating methods, such as retroviruses and lenti-
viruses, and non-genome integrating methods, such as reprogramming
mediated by Sendai virus, episomal vectors, mRNA/miRNA and small
molecules (Augustyniak et al., 2014; Wu et al., 2013), but in the end,
the hiPSC should recapitulate the main properties of hESC, namely: 1)
ability to self-renew; and 2) the ability to form cells from each of the
three germ layers. For research lines with potential clinical applica-
tions, the quality of the hiPSC cells is of utmost importance. Repro-
gramming to hiPSC can introduce genetic aberrations, which could
have detrimental downstream effects for disease modeling and clinical
safety. For example, long-term passaging of PSC can lead to the selec-
tion of cells with chromosomal duplications that support a growth ad-
vantage (Merkle et al., 2017; Ben-David et al., 2014). These genetic
aberrations may preclude usage of such lines for clinical application, as
there is a risk that these lines could form tumors in the patients.
The versatility of deriving specific cell types from hPSC is especially
promising for the treatment of diseases in which the desired therapeutic
cell types are not accessible in practice. These cell types include retinal
pigmented epithelia (for retinal diseases) and myoblasts (for myopathy)
(Mitjavila-Garcia et al., 2005). In principle, a patient's own iPSC can be
generated as a source of autologous cells; however, in practice, devel-
oping a patient-specific line for individual cell therapy is too expensive
and may take too long as an ad hoc approach for an effective ther-
apeutic intervention. Rather, it has been proposed that HLA homo-
zygous hiPSC banks could be established to provide allogenic im-
munocompatible cells on-demand (Wilmut et al., 2015) (see also Lanza
et al., 2019). There are also more radical approaches to providing “one-
size-fits-all” immunocompatible hPSC lines, such as the creation of
hPSC lines that lack MHC class I and II molecules using genome editing
methodologies (Mitjavila-Garcia et al., 2005).
1.2. Uncomfortable bedfellows: shady stem cell clinics
Though stem cell therapies have been successfully applied in the
form of hematopoietic stem cell transplantation for over 30 years
(Thomas, 1999), and current availability of hPSCs affords the possibi-
lities of off-the-shelf products for cell-specific therapy, disease mod-
eling, and drug testing, stem cell therapy is in danger of becoming a
victim of its own success. The hype surrounding stem cell research has
attracted false claims in the form of stem cell clinics that market un-
proven treatments to susceptible patients. In an act of “scienceploita-
tion” (Murdoch et al., 2018), these clinics use the publicity from basic
science, such as the discovery of hiPSC cells, and feed off the success of
other stem cell treatments, such as bone marrow transplants to treat
acute myeloid lymphoma (AML), to sell their dubious stem cell treat-
ments. Many of these stem cell clinics operate as direct-to-consumer
businesses and charge hefty fees (Glassberg et al., 2018; Knoepfler and
Turner, 2018), spawning a whole new stem cell tourism industry
(Glassberg et al., 2018; Knoepfler and Turner, 2018; Rubin, 2018).
Furthermore, unscrupulous stem cell clinics often use “tokens of sci-
entific legitimacy”, such as testimonials, registration of patient-spon-
sored clinical trials on ClinicalTrials.gov, and certifications or accred-
itations to appear as regulated, legitimate stem cell clinics (Gunter
et al., 2010; Sipp et al., 2017; Sugarman et al., 2018). Mass media
stories of celebrities who partake in stem cell tourism appear to endorse
these unregulated treatments, with little critical discussion of the actual
efficacy and safety of the treatment (Du et al., 2016; Rachul and
Caulfield, 2015). Unregulated stem cell treatments have caused adverse
events such as blindness, tumor formation, brain hemorrhaging and
even death (Bauer et al., 2018).
In response to the growing number of predatory stem cell clinics and
adverse events being reported in the scientific literature and the mass
media, regulatory authorities have attempted to tighten up regulations.
In the EU, the European Union Tissue and Cells Directives (EUTCD) was
initiated in 2004 (The European Parliament and the Council of the
European Union, 2019) to regulate the use of tissues and cells intended
for human application and covers the early stages of hPSC derivation
(see Abranches et al., 2020). Subsequently, all cell therapy products
became subject to regulation as Advanced Therapy Medicinal Products
(ATMP) in 2007, with a compliance transition period from 2008 to
2011 (The European Parliament and the Council of the European
Union, 2018). In 2017, the FDA closed some regulatory loopholes
surrounding the use of human cell- and tissue-based products (HCT/P)
(Charo and Sipp, 2018). These most recent regulations are unavoidably
applicable to the up-and-coming hPSC-derived cell-based therapies.
1.3. Stakeholder engagement
To ensure a smooth transition of PSC-derived cell-based therapies to
market, all stakeholders, including basic and clinical researchers, stem
cell banks, industry, regulatory authorities and finally the end-users
(namely patients who would benefit from the therapy), must diligently
participate in the development of cell-based therapies. Proponents of
PSC-derived cell treatments must actively develop quality standards for
Table 1
Professional societies, institutions or resources for stem cell research and applications.
Organization Description Resources
International Society for Stem Cell
Research (ISSCR)
global professional society of stem cell scientists and
clinicians
information brochures for prospective patients of stem cell treatments
(International Society for Stem Cell Research (ISSCR)); guidelines for clinicians
regarding stem cell treatments (International Society for Stem Cell Research
(ISSCR))
Eurostemcell EC-funded science communication project for stem cells
and regenerative medicine
diverse on-line resources for the general public and educational material
(EuroStemCell)
California Institute for Regenerative
Medicine (CIRM)
an institute created by the State of California to fund
stem cell research for therapies
information for the general public about stem cell biology and stem cell
treatments (California Institute for Regenerative Medicine (CIRM))
International Society for Cell & Gene
Therapy (ISCT)
global professional society of researchers, clinicians,
regulators, technologists and industry partners
annual reports on cell and gene therapy market authorizations, collection of
news announcements on stem cell treatments (ISCT)
Global Alliance for iPSC Therapy
(GAiT)
international consortium of public and private partners
to support the development of hiPSC therapies
quality control guidelines for clinical-grade hiPSC lines (Global Alliance for
iPSC Therapies (GAiT), ISCI; Sullivan et al., 2018)
International Stem Cell Initiative
(ISCI)
worldwide collaborative effort of basic scientists to
establish standards for PSC-based applications in human
medicine
systematic performance testing to address the robustness of stem cell protocols
across diverse laboratories, with the aim of establishing consensus protocols
(ISCI)
International Stem Cell Banking
Initiative (ISCBI)
global network of stem cell banks publication of guidance documents regarding the international standards for
banking, characterisation and testing (ISCBI)
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stem cell products in consultation with regulators. Representatives from
academia and industry have organized themselves into professional
societies such as the ISSCR, ISCT, ISCI, GAiT and ISCBI (Table 1), with
the aim of safeguarding the development of safe and effective PSC-de-
rived cell products by working towards an international consensus on
the best practices and standards for cell therapies (Andrews et al.,
2015). The public must have easy access to trustworthy information
about stem cell treatments. Public engagement by academic organiza-
tions is key to educating and providing reliable information on stem cell
research and stem cell treatments to the public at large (Table 1). By
arming patients with knowledge, patients can empower themselves and
make better decisions in consultation with their physicians.
Concurrent to these developments, advances in the diversity and
availability of hPSC lines should contribute to a large resource of re-
agents and knowledge on the particular properties and characteristics
of hPSC lines. Joint initiatives with the European Commission (EC) and
industry have spawned projects to generate and bank hiPSC in a
quality-controlled manner (see also other chapters Sullivan, in press).
Of great interest for disease modeling and drug testing are hiPSC lines
derived from donors with a diagnosed disease and their gene-corrected
hiPSC lines as isogenic controls, or alternatively, lines from normal
donors and their genetically modified lines containing one or more
disease-associated mutations. In the joint banking initiative European
Bank for induced Pluripotent Stem Cells (EBiSC) (De Sousa et al., 2017),
over 1100 hiPSC lines have been earmarked for banking, which include
those banked directly by the EBiSC consortium (as commissioned or
existing hiPSC lines) and hiPSC lines obtained through collaborations
with other projects (BADiPS, HipSci, StemBANCC, and UnTangle2).
Approximately 70% of these lines (Fig. 1) are actively stocked and
distributed by the European Collection of Authenticated Cell Cultures
(ECACC (Public Health England, 2019)). The parental hiPSC lines are
largely derived from normal donors and donors with neurological dis-
eases, followed by hiPSC lines derived from other disease groups, in-
cluding blood, cardiovascular, eye, multi-systemic syndromes and
muscular diseases (Fig. 2). Six parental hiPSCs have been genetically
modified, such as introduction of a genetic modification associated with
disease, giving rise to a total 42 pairs of isogenically modified subclone
lines (Table 2). All of these parental and subclone hiPSC lines are re-
gistered in hPSCreg and are banked, making these lines an excellent
resource for disease modeling studies.
1.4. Science-based medicine: quality PSC-derived cells for clinical trials
As of February 2019, there were 37 clinical trials involving PSC-
derived cell types for macular degeneration and other eye disorders,
which are the most treated indication in current clinical trials with
hPSC derivatives (Schwartz et al., 2015; Song et al., 2015; Mandai
et al., 2017; Mehat et al., 2018), but trials for other conditions such as
spinal cord injury, diabetes, heart disease (Menasché et al., 2018),
graft-versus-host disease and Parkinson’s disease are also in progress
(Table 3) (Guhr et al., 2018). Thirty-one trials used hESC-derived cells,
and the remaining six involved hiPSC derivatives (including one auto-
logous application). Most trials are being carried out in the USA (12
trials), with China and the UK with 7 and 5 clinical trials, respectively.
Japan is leading in performing clinical trials involving hiPSC-deriva-
tives. Five of the six trials using hiPSC-derivatives are located in this
country. All of these hPSC-derived cell products are still in the stages of
drug development (Phase I/II/III). Currently, not a single hPSC-derived
cell product has reached the marketing authorization stage.
Some organizations have announced upcoming clinical trials with
hiPSC-derived cardiac cells for ischemic heart disease (Osaka
University) and with hiPSC-derived killer T cells (Thyas Co. Ltd.) and
natural killer cells for immunotherapy for some kinds of cancer and for
hematologic malignancies (Fate Therapeutics, Inc.) (The Asahi
Shimbun, 2018; Globe Newswire, 2019; Fate Therapeutics, 2019). It
should be noted that collecting information from the clinical trials in
progress or about to start is difficult as data are not available in the
literature. When available, press releases or other non-scientific sources
have been used and as a consequence, the scenario described is prob-
ably very incomplete. Establishing an efficient registry for clinical trials
with hPSC derivatives is therefore a foremost need.
Human PSC-derived cell therapies present new regulatory chal-
lenges. hPSC-derived cells are produced in multiple steps of cell en-
gineering and sometimes genetic engineering, which may span a total
time culminating in weeks or months from cell reprogramming to di-
rected differentiation, in order to manufacture the final product with
the desired properties. At any point in the long chain of hPSC-derived
cell product development, unexpected genomic alterations may accu-
mulate in the cells, leading to an uncertain risk for the recipient of the
cell therapy. Considering that the cells may persist for the rest of re-
cipient's life, consideration must be given to the purity and stability of
the hPSC-derived cells such that the cell product is neither con-
taminated with nor differentiates to unwanted cell types (Petricciani
et al., 2017). Therefore, the quality of both the hPSC cells and the
specific cell types that have been derived from the hPSC cells must be
proven before the hPSC-derived cells can be safely used in clinical
trials. It is therefore of utmost importance that certain standard criteria
must be fulfilled to ensure high quality hPSC cells, and that this data is
transparent and comparable to hPSC lines generated worldwide. A si-
milar high standard of cell quality is necessary for their use in disease
modeling and drug screening, as genetic alterations, for example, can
severely bias the models and test data.
To strengthen public and scientific assurance in hPSC-based
Fig. 1. Banked EBiSC Lines in hPSCreg. The EBiSC consortium banked 843
hiPSC lines, which can be categorized by origin: General Deposit = a regular
cell line deposit, which was not associated to a specific project within EBiSC;
HotStart = a set of hiPSC lines initially banked by EBiSC to establish the op-
erational banking workflow (De Sousa et al., 2017); BADiPS = a CRACK IT
innovation platform project for bipolar affective disorder (CRACK IT, 2019);
HipSci = a large collection of well-characterised hiPSC lines for research
(Streeter et al., 2017); StemBANCC = a large collection of well-characterised
lines for disease modeling and toxicology studies (Morrison et al., 2015); Un-
Tangle2 = a CRACK IT innovation platform project for Alzheimer's disease
(CRACK IT, 2019); NCLC = new cell lines commissioned by the EBiSC con-
sortium; * = hiPSC lines were banked by EBiSC as part of an hiPSC project
collaboration.
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therapies, steps must be taken to ensure foremost patient safety. The
first ever clinical trial involving hiPSC-derived cells was led by Masayo
Takahashi in Japan. In this trial, the transplantation of hiPSC-derived
retinal pigmented epithelial cells in a second patient (male) was halted,
partly because the cells were found to contain deletions on the X
chromosome (Mandai et al., 2017). Though the authors of the study
admitted that the cancellation of the second transplantation was per-
haps “unnecessarily strict” (Mandai et al., 2017), the first patient had
no serious complications one year after therapy, and this clinical trial in
itself was a milestone for regenerative medicine (Reardon and
Cyranoski, 2014). Taking advantage of a change in the Japanese law, by
which the Japanese government decided to only allow the use of
allogeneic, matched hiPSC from cryobanks, the Takahashi team put in
place a new clinical trial for the same indication using allogenic hiPSC.
1.5. Securing the pathway to successful clinical translation
The smooth implementation of hPSC-based cell therapies will re-
quire a concerted effort from all stakeholders with a vested interest in
safe and effective clinical translation of hPSC-based cell therapies.
Human PSC lines with the “right stuff”, in terms of ethical provenance,
biological quality and safety, cell line authenticity and immunological
properties, are in demand. Background information regarding the
generation of these cell lines must be available, including traceable
Fig. 2. Overview of EBiSC banked parental hiPSC lines registered in hPSCreg and associated diseases with these lines. Parental hiPSC lines were generated from
donors with and without disease. Each column represents the projects and each row represents the disease status, which is grouped into eight broad categories:
normal (red), blood (blue), cardiovascular (green), eye (purple), metabolic (orange), multi-system syndrome (yellow), muscular (brown), and neurological (pink).
The diameter of the coloured circles is approximately proportional to the actual number of lines, which is printed in the middle of each circle. Abbreviations:
CPVT = catecholaminergic polymorphic ventricular tachycardia; 16p11.2 deletion syndrome = Chromosome 16p11.2 deletion syndrome, 220kb (distal 16p11.2
microdeletion syndrome). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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protocols for derivation and maintenance, and thoroughly documented
genetic modifications, if performed. Moreover, banked hPSC lines are
added-value reagents that have the potential to augment basic and
clinical research by encouraging the re-use of existing lines, thereby
conserving resources. Having this body of information is imperative to
enable the evaluation of hPSC lines for their potential and suitability in
specific clinical applications. A central resource that contains hPSC line
information in a standardized manner would greatly enhance clinical
translation of hPSC lines by facilitating the search for suitable hPSC
lines and simplifying the information gathering process for the compi-
lation of a potential clinical product dossier. The Human Pluripotent
Stem Cell Registry (hPSCreg) provides a framework to collect and store
hPSC line data to fulfill these needs.
2. The Human Pluripotent Stem Cell Registry
2.1. Enabling qualified pluripotent stem cell lines
The Human Pluripotent Stem Cell Registry was launched in 2007 to
facilitate an overview of pluripotent stem cell lines used in research
funded by the European Commission (EC) (Seltmann et al., 2016). Since
its inception over a decade ago, hPSCreg has grown to contain 739
human ESC and 1868 human iPSC lines from 30 countries worldwide
(as of February 2019). The Registry addresses several important aspects
surrounding hPSC lines:
Donor consent: the conditions under which consent were obtained
and what was consented to are fundamental to the ethical and lawful
usage of the biological materials.
Applicable local laws: the geographical location where the tissue
donations were made and the hPSC cells were derived, as well as the
date of derivation (especially in the case of hESC), may influence hPSC
line usage according to local laws.
Biological origin and derivation: clinical and phenotypic data from the
donor of the source material, the materials and methods used to derive
the hPSC, as well as any genetic modifications that may have been
introduced, have a bearing on the line's suitability for downstream
applications, such as drug-testing, disease modeling or cell therapy. The
starting biological material and subsequent experimental procedures
must be traceable.
Evidence of pluripotency: as there are a diverse number of tests
available to show self-renewal and pluripotency, the hPSC line must
satisfy a minimum set of criteria to demonstrate these characteristics.
Authenticity: the identity of the line in further research should be
unambiguous through the use of short tandem repeat (STR) typing and
standard cell nomenclature.
Standard data collection: the data surrounding the hPSC lines should
Table 2
Genetically modified hiPSC lines banked by the EBiSC project.
Parental line standard name Donor disease status Standard name of modified line Disease associated with genetic modification Modified Locus
BIONi010-C normal BIONi010-C-10 monogenic diabetes HNF1A
BIONi010-C-11 monogenic diabetes HNF1A
BIONi010-C-12 monogenic diabetes HNF4A
BIONi010-C-13 modification not disease-related AAVS1
BIONi010-C-15 modification not disease-related AAVS1
BIONi010-C-17 Alzheimer's disease TREM2
BIONi010-C-18 inflammatory diseases and cancer TBK1
BIONi010-C-2 Alzheimer's disease APOE
BIONi010-C-3 Alzheimer's disease APOE
BIONi010-C-4 Alzheimer's disease APOE
BIONi010-C-5 Alzheimer's disease CD33
BIONi010-C-6 Alzheimer's disease APOE
BIONi010-C-7 Alzheimer's disease TREM2
BIONi010-C-8 Alzheimer's disease TREM2
BIONi010-C-9 Alzheimer's disease CD33
BIONi037-A normal BIONi037-A-1 Alzheimer's disease APOE
BIONi037-A-2 Alzheimer's disease APOE
BIONi037-A-3 Alzheimer's disease APOE
BIONi037-A-4 Alzheimer's disease APOE
EDi001-A Parkinson's disease EDi001-A-1 Parkinson's disease SCNA
EDi001-A-2 Parkinson's disease SCNA
EDi001-A-3 Parkinson's disease SCNA
EDi001-A-4 Parkinson's disease SCNA
SIGi001-A normal SIGi001-A-1 modification not disease-related SLC17A7
SIGi001-A-10 *multiple neurodegenerative diseases MAPT
SIGi001-A-11 *multiple neurodegenerative diseases MAPT
SIGi001-A-12 frontotemporal dementia MAPT
SIGi001-A-13 Alzheimer's disease MAPT
SIGi001-A-2 modification not disease-related SLC17A7
SIGi001-A-3 frontotemporal dementia MAPT
SIGi001-A-4 frontotemporal dementia MAPT
SIGi001-A-5 frontotemporal dementia MAPT
SIGi001-A-6 frontotemporal dementia MAPT
SIGi001-A-7 frontotemporal dementia MAPT
SIGi001-A-8 *multiple neurodegenerative diseases MAPT
SIGi001-A-9 *multiple neurodegenerative diseases MAPT
STBCi006-A Alzheimer's disease STBCi006-A-1 Alzheimer's disease APOE
STBCi006-A-3 Alzheimer's disease APOE
STBCi006-A-4 Alzheimer's disease APOE
UKBi011-A Alzheimer's disease UKBi011-A-1 Alzheimer's disease APOE
UKBi011-A-3 Alzheimer's disease APOE
UKBi011-A-4 Alzheimer's disease APOE
* Associated with three neurodegenerative diseases: corticobasal degeneration/FTDP-17 (Frontotemporal dementia and parkinsonism linked to chromosome 17)/
progressive supranuclear palsy.
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follow the FAIR data principles, such that the data is findable, acces-
sible, interoperable and re-usable according to the guidelines proposed
by the Future of Research Communications and e-Scholarship
(FORCE11) (FORCE11, 2018).
All of these aspects lend transparency to the process of making and
using these lines for research and clinical applications. HPSC lines that
meet a minimum criteria for ethical provenance and pluripotency are
eligible to receive certificates, which are recognized by EC funding
bodies as evidence for qualified hPSC lines for use in EC-funded re-
search. For researchers, the registration of their hPSC lines in hPSCreg
gives them more visibility and recognition for their work, as the lines
receive unique names and this traceable information is shared between
many databases, such as Cellosaurus (hosted by the Swiss Institute of
Bioinformatics (Bairoch, 2018) and BioSamples (hosted by European
Molecular Biology Laboratory - European Bioinformatics Institute
(European Molecular Biology Laboratory, xxxx). Furthermore, re-
searchers have the option of publishing their lines as a lab resource in
the journal Stem Cell Research. For funders and industry, hPSCreg gives
an overview of which lines are in use and who is producing hPSC lines,
such that future funding calls can be designed to encourage future de-
velopment of hPSC lines and their derivatives, for example, into disease
areas of major public health concern. Also, there are opportunities to
quantify the amount of publicly funded hPSC-related research and the
success of its outcomes in terms of clinical translation and technology
transfer. For regulators, hPSCreg provides a convenient oversight of the
generation and production of starting materials for future hPSC-derived
cell therapy products, such that regulators have relevant information to
prepare for clinical trials involving novel hPSC-derived cell therapy
products. Stakeholders from the entire range of the clinical develop-
ment process can benefit from the registration of hPSC lines in hPSCreg.
2.2. Registering lines in hPSCreg
To facilitate data collection, hPSCreg has implemented a self-reg-
ulating user management process. To register a hPSC line, the organi-
zation that generated the line must be registered in hPSCreg. Current
details of the user registration process can be found in the “Quick-Start
Guide” on the hPSCreg website (The Human Pluripotent Stem Cell
Registry (hPSCreg), 2018). Briefly, the user management system is self-
regulating in that it allows previously registered hPSCreg users to ap-
prove user registrations originating from the same institution, in a peer-
to-peer trust mode. The user management system also provides a way to
automatically use the generating organization's acronym in composing
the standard nomenclature of the hPSC lines.
The first step in registering a line is to acquire an automatically
generated standard name by choosing the hPSC line type (currently
embryonic stem cell or induced pluripotent stem cell line), the gen-
erator institution, and relations to other hPSC lines in hPSCreg (i.e.
whether it is another hPSC line from a previously registered donor or it
is a subclone of another previously registered hPSC line). Second, all
data associated with the hPSC line can be entered. The on-line regis-
tration of hPSC lines is divided into eight headings as outlined in
Table 4, and a brief overview of the registration process is depicted in
Fig. 3. The user-entered data can be saved at any point in the data entry
process, so that it is possible to resume data entry at a later time. Al-
ternatively, if a user wishes to register multiple cell lines at a time, a
block registration of lines could be carried out by contacting hPSCreg
directly for a mass data import (see also the “Access to Data” section
below). Each section in the data entry process has some required fields,
which must be provided before the user can submit the line for vali-
dation by the hPSCreg validator. These mandatory fields include key
information, such as the conditions of donor consent and the cell line's
permitted uses and availability, characterization of pluripotency, and
genetic information. A detailed description of the mandatory fields can
be viewed in the “Cell Line Registration Quick-Start Guide” from the
hPSCreg website (The Human Pluripotent Stem Cell Registry (hPSCreg),
2018). Once the mandatory information fields have been filled, the
registrant can submit the line for validation. The hPSCreg validator will
evaluate the data provided about the hPSC line and validate the line
according to the criteria for validation in the “Documents and Gov-
ernance” section of the hPSCreg website (The Human Pluripotent Stem
Cell Registry (hPSCreg), 2019). Data from lines that have been regis-
tered in hPSCreg, but are missing mandatory information and have not
yet been submitted for validation, will only publicize basic information
about the hPSC line, such as the standard cell line name, alternative
names and the generator and owner of the line. Additional information
from hPSC lines, such as anonymized donor information and details
about the cell line derivation, becomes publicly visible as soon as the
line has been submitted for validation. Finally, submitted lines that
meet ethics and pluripotency criteria are eligible to receive certificates,
which can be obtained from the hPSCreg website.
2.3. Registering projects and clinical trials in hPSCreg
The results of publicly-funded research are often disseminated
through publications in scientific journals or funding agency reports. To
provide more transparency towards the use of hPSC lines, users can
register research projects in hPSCreg by entering basic information
about a project (i.e. title, short name, description, funder, institution)
and then associating already registered hPSC lines with the project
information. This information will support communication between
laboratories working on similar topics, or using the same hPSC lines,
and thus help to reduce redundancies and build synergies. In addition,
project certificates together with cell line certificates provide con-
fidence to the funders and publishers of projects that acceptable ethical
and scientific standards are being observed (Fig. 4). The EC currently
requests these certificates as funding requirements. Although it is not
currently required by other funding agencies to register projects where
hPSC lines are used, the project registration is open to all users. As of
February 2019, hPSCreg had 123 registered projects, which are asso-
ciated to 1789 unique hPSC lines. The most popular cell lines associated
with projects were all hESC lines (WAe009-A, WAe001-A, and
UOSe003-A).
A long-term goal of regenerative medicine is to be able to derive
specific cell types from hPSC lines and to use these hPSC-derived cells in
cell therapy or as part of medical devices. The clinical translation of
hPSC-derived cells is still in its infancy, with currently (as of February
2019) no ongoing clinical trials involving hPSC-derived cells beyond
Phase III anywhere in the world. hPSCreg enables registered users to
record clinical trials and the associated source hPSC lines used, as well
as to provide information on the specific therapeutic cell type deriva-
tion. By storing this information in a single resource, it is possible to
track the success of hPSC lines in contributing to validated cell thera-
pies. The hPSCreg clinical trial registry provides specific information,
which is not readily available in other resources, and encourages ex-
change on quality and performance data of source cell lines and ther-
apeutic cell products, provides insights into regulatory compliance
handling and provides transparency and feedback options.
2.4. Access to data
hPSCreg strives to follow the FAIR principles (Wilkinson et al.,
2016) as proposed by the FORCE11 Initiative, to make the data
“Findable, Accessible, Interoperable, and Reusable”. The Registry sup-
ports the FAIRification of scientific data for hPSC research to ensure
optimal reprocessing of human- and machine-readable research data.
To increase the discoverability of hPSCreg as a data resource for
hPSC lines, hPSCreg is registered in the global registries of research
data repositories such as re3data.org and fairsharing.org (re3data.org.,
xxxx, fairsharing.org., xxxx, identifiers.org., xxxx). The data within
hPSCreg is findable, as each cell line in hPSCreg is assigned with a
standard name that acts as a globally unique and persistent identifier.
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Furthermore, every cell line is annotated with extensive metadata using
a “plurality of accurate and relevant attributes”, as outlined by the
FORCE11 initiative. Data completeness and correctness are manually
checked for each line after submission based on a defined set of
minimal criteria (see hPSCreg section on “Documents and Governance”
(The Human Pluripotent Stem Cell Registry (hPSCreg), 2019). These
criteria may be adjusted based on feedback from the hPSCreg com-
munity, for example, the hPSCreg Committee of National Re-
presentatives, a high-level advisory group of hPSC–scientists.
The standard name is linked to a unique Biosample ID for both cell
line and donor. The cell lines can be searched on the webpage by name
or by associated (meta)data. Given other names, synonyms, and iden-
tifiers, an API can be used to find the official hPSCreg standard unique
identifier of cell lines. For example, the well-known hESC line “H9″ has
the standard identifier ”WAe009-A“.
Basic information about a cell line (i.e. generating institution,
hESC/hiPSC, donor number, subclone number) is publicly accessible on
the website in human-readable form and by various RESTful web ser-
vices (Fielding, 2000) (also known as web APIs) as soon as the cell line
name has been registered by the user. Additional cell line information
(i.e. ethics of tissue donation, biological properties of the cell line) will
become public once the line has been submitted. Data that could be
used to identify the donor like STR data is not made publicly available.
Genetic data are made available for third-party use, subject to the terms
of donor consent and approval by a data access committee. All data
collected by hPSCreg are stored according to the General Data Protec-
tion Regulation (GDPR).
Whenever possible, ontology terms are used to annotate the cell line
information. HPSCreg works with partners to find a robust solution for
automated data transfer between the available data sources and targets.
Data exchange with several partners is implemented mainly using the
data exchange format JSON (Internet Engineering Task Force (IETF),
2017; ECMA International, 2017) which is an open standard and a
human readable text format. hPSCreg has on-going collaborations for
data exchange with Cellosaurus (Bairoch, 2018), Cellular Dynamics
(Fujifilm, xxxx), eagle-i (Harvard Catalyst, xxxx), EBI Biosamples
(Faulconbridge et al., 2014), EBiSC (De Sousa et al., 2017), GAiT
(Global Alliance for iPSC Therapies (GAiT), xxxx), RIKEN (RIKEN,
xxxx), Rutgers (RUCDR Infinite Biologics, xxxx) and SKIP (Stemcell
Knowledge & Information Portal (SKIP), xxxx).
The existing APIs allow the reuse of the available data by other
projects. Cellosaurus is already using the API as a data source for their
platform, resulting in on-going data checks between Cellosaurus and
hPSCreg, which increases the quality of cell data annotation and ex-
pands the visibility of hPSC lines. As of January 2019, approximately
30% of the hPSC lines collected by Cellosaurus were also registered in
hPSCreg. The Integrated Collection of Stem Cell Bank data (ICSCB)
(Fujibuchi Laboratory, xxxx) is using the MIACARM (Sakurai et al.,
2016) API for their platform-independent cell line search.
2.5. Incentives for the registration of lines in hPSCreg
hPSCreg has to balance registrant compliance with the information
burden placed on the registrant. Users are less likely to register lines if
too much information is required for registration; however, there are
prospective downstream benefits to line registration in hPSCreg. By
registering their lines in hPSCreg, users can demonstrate their research
output and quality, and increase the value and recognition for their
work. Validation certificates issued by hPSCreg for qualified cell lines
speaks to the ethical and scientific quality of hPSC derivation. The trend
towards more transparency in terms of open science and open data will
become more pronounced, as more scientific and medical journals
embrace the FAIR data principles. Authors will be encouraged to
thoroughly document hPSC lines generated in their manuscripts, in the
Table 4
Organization of hPSC-associated data in hPSCreg.
Heading Examples of Data Fields Examples of applicable metadata items or standards
General Information Cell line name* Standard hPSC line name (Kurtz et al., 2018)
Generator institution*
Biosamples ID of cell line* BioSamples (Faulconbridge et al., 2014)
Publications associated with the cell line PubMed Identifier (NCBI)
Is the cell line readily obtainable for third parties?*
Donor Information Sex* Experimental Factor Ontology (Malone et al., 2010)
Biosamples ID of donor* BioSamples (Faulconbridge et al., 2014)
Diagnosed diseases Experimental Factor Ontology (Malone et al., 2010), Human
Phenotype Ontology (Köhler et al., 2017)
Ethics/Usage Has consent been obtained from the donor of the tissue from which iPS cells have been
derived?*
Automatable Discovery and Access Matrix (ADA-M) (Global
Alliance for Genomics and Health, 2018)
Was the consent voluntarily given by the donor, custodian or parents?
Does consent expressly prevent derivation of iPS cells?*
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being
made available to researchers anywhere in the world?*
Has a favourable opinion been obtained from a research ethics committee, or other ethics
review panel, in relation to the PROPOSED PROJECT, involving use of donated material or
derived cells?*
Derivation Cell type of the source cell (fibroblast, erythroblast, …)* Experimental Factor Ontology (Malone et al., 2010), Cell
Ontology (Bard et al., 2005)
Vector type for reprogramming* Minimum Information About a Cellular Assay for
Regenerative Medicine (MIACARM) (Sakurai et al., 2016)
Available as clinical grade MIACARM
Culture Conditions Surface coating MIACARM
Feeder cells MIACARM
Culture conditions: Medium* MIACARM
Characterisation Analysis of undifferentiated cells: marker expression* MIACARM
Differentiation potency (Endoderm, Mesoderm, Ectoderm)* MIACARM
Microbiology/virology screening MIACARM
Genotyping Has the cell line karyotype been analysed?*
Human Leukocyte Antigens (HLA) typing HLA Nomenclature (Marsh et al., 2010)
Short Tandem Repeat (STR) typing*
Genetic Modification Genetic modifications related to a disease or phenotype context* Sequence Variant Nomenclature (den Dunnen et al., 2016)
*Data must be entered in these mandatory fields before a line can be submitted for validation by the hPSCreg validator.
N. Mah, et al. Stem Cell Research 47 (2020) 101887
8
Fig. 3. Overview of Cell Line Registration in hPSCreg. First, a unique standard cell line name is assigned to the new hPSC line. The standard nomenclature contains
human-readable information such as the acronym of the organization that generated the hPSC line, the hPSC type (i.e. “i” for induced pluripotent stem cell line and
“e” for embryonic stem cell line), a suffix indicating the donor, such that lines from the same donor can be traced, and a second suffix indicating that a line is a
subclone of an hPSC line. In the context of hPSCreg, a subclone is defined to be any PSC line which has been genetically modified, such as a modification to contain a
disease mutation or reporter gene construct. Second, the user is prompted to enter contact information for the cell line, donor information and data about the hPSC
line. Mandatory information is shown in green boxes. Once all mandatory information has been entered, the user can submit the line for validation (step 3). The
hPSCreg validator will go through all of the mandatory information and validate the hPSC line if all data satisfies the validation criteria (step 4). Finally, lines that
pass validation are eligible to receive certificates attesting the ethical and biological provenance of the hPSC line. Certificates can be obtained from the hPSCreg
website. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 4. Examples of certificates issued by hPSCreg. A. Project certificate. B. hESC line certificate. C. hiPSC line certificate.
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same manner that transcriptome data should be deposited in a public
data repository and referenced by a persistent identifier. As a central
registry, hPSCreg makes this documentation possible as a FAIR re-
source, and reduces the burden of repeated deposition of the same in-
formation in multiple sources. As technologies progress, hPSC deriva-
tion will also become routine to the point where the derivation itself no
longer merits a separate stand-alone publication. Publishing a qualified
line on hPSCreg offers researchers way to have their lines disseminated
and acknowledged in a manner that exceeds the superficial level of
ethical evaluation carried out by journal peer review. With hPSC line
data in a central registry, it will be much easier for all parties to find
hPSC lines most relevant for a specific purpose and lead to more
widespread use of hPSC lines. Especially, there are gains to be made
through a match-making process between cell line generators and cell
line seekers looking for a particular cell line for clinical translation.
3. Summary
3.1. Future outlook for hPSC data
The meticulous and judicious data collection of hPSC data must
keep pace with advances and trends in technology, which will impact
the clinical translation of hPSC-derived cells. To accommodate this, it is
likely that hPSC line information must be collected in greater detail and
new fields or concepts will have to be introduced in hPSCreg. For in-
stance, the integration of somatic nuclear hPSC and parthenogenetic
hPSC lines into hPSCreg will necessitate extensions to the standard
nomenclature to properly annotate these kinds of hPSC lines. Indeed,
parthenogenetic PSC lines are already being used in pre-clinical and
clinical studies (Wang et al., 2018; Gonzalez et al., 2016; Hayek, 2018).
Increased use of genome editing techniques, for example by CRISPR/
Cas, enables researchers to routinely edit a cell line's genome to in-
troduce mutations or to normalize existing disease mutations from
patient material. Unintentional yet inevitable genetic changes may
occur in hPSC line during propagation and differentiation. A risk as-
sessment of genetic changes will be made easier by the falling costs of
high-throughput DNA sequencing (Wetterstrand, 2018), which will
make sequencing affordable and accessible to more researchers and
enable more whole genomes and epigenomes to be analyzed at near-
base resolution for any cell line. Guidelines regarding the acceptable
extent of off-target gene editing or even what kinds of intentional or
non-intentional modifications observed by epi-/genome sequencing
constitutes an acceptable risk have not been defined and are the subject
of on-going discussions in the clinical translation field (Keep off-target
effects in focus, 2018; Andrews et al., 2017). In this regard, the Registry
can act as an anchor to link genetic mutations and variations and re-
gistered lines such that a risk assessment meta analysis may be carried
out.
3.2. Setting the stage for transparency in pluripotent stem cell research and
clinical translation
The Human Pluripotent Stem Cell Registry was established with
support from the EC to provide transparency in human pluripotent stem
cell research. This is accomplished by: 1) collecting a standard set of
data addressing ethical procurement of human material for hPSC gen-
eration, derivation and pluripotency of the hPSC lines, and usage of the
lines as stipulated by the donor consent; and 2) using standard terms
and ontology to annotate the hPSC-associated data, thus enabling
comparability between hPSC lines generated from different institutions
and countries. For instance, the adoption of specifications, such as
standard cell line nomenclature and MIACARM, will improve data ex-
change with other stem cell databases and facilitate targeted cell line
searches. Moreover, the use of Biosample Donor IDs and STR profiles
should make it possible to generate trackable cell line pedigrees across
all registered lines. While hPSCreg considers basic evidence of
pluripotency for validation, such evidence may not reveal a line's un-
derlying peculiarities—not all hPSC lines are equal (Lee et al., 2014;
Kim et al., 2011). Some have predilections towards cell types of certain
lineages due to epigenetic memory, and in fact this knowledge could be
advantageous for some applications (Bar-Nur et al., 2011). Practical
know-how gained while working with the lines can be valuable in-
formation to cell line seekers. To this end, hPSCreg encourages research
community involvement by providing a feedback comment field for
hPSC lines, where users can publicly share their cell line experiences.
The transparent process of generating hPSC lines will demonstrate
the hPSC line quality and its appropriate usage for potential applica-
tions. As a biological example, older hiPSC lines may have been re-
programmed by retroviral vectors, which randomly integrate into the
genome and may have unforeseen deleterious properties, such as tu-
morigenicity, when used as a source for hiPSC-derived lines. Such lines
may be better suited for non-cell therapy applications, such as func-
tional cells contained within a medical device. Additionally, an hPSC
line may have limited applications due to its allowed usage as stated in
the donor consent, for example, restriction to non-commercial use only.
Therefore, transparency in hPSC data is important to avoid downstream
usages incompatible with the biological and legal properties of the cell
line.
Apart from cell-based therapy, hPSC lines will find increasing utility
as the source material for hPSC-derived cell types for use in in-
dividualized disease modeling and drug screening. Both approaches
will require the integration clinical data from the donor patient and the
hPSC data, which together will be highly informative for the quality of
the disease model and the accuracy of the drug screening process. These
developments constitute the growth of a new data sphere, which is
currently divided into several silos (Kurtz et al., 2019). HPSCreg is well-
positioned to act as a key central resource for the integration of new
data in a FAIR-compliant manner.
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